Shares of Akero Therapeutics Inc. AKRO, +4.78% soared 101.1% in premarket trading on Tuesday after the company said its experimental treatment for nonalcoholic steatohepatitis met a primary and secondary endpoint in a Phase 2b clinical trial. NASH is a liver disease. “The magnitude and general consistency of results observed across the Phase 2a BALANCED and Phase 2b HARMONY studies increase the probability of success in Phase 3 and position EFX to potentially be a foundational monotherapy for patients with NASH,” Dr. Stephen Harrison, one of the study’s investigators, said in a news release. Akero’s stock is down 42.0% this year through Monday’s close, while the broader S&P 500 SPX, +1.06% has declined 13.7%.
